Literature DB >> 32970472

Efficacy and safety of percutaneous microwave ablation for hepatocellular carcinomas <4 cm in difficult location.

Amar Mukund1, Ravindran Ramalingam1, Karan Manoj Anandpara1, Yashwant Patidar1, Rajan Vijayaraghavan2, Shiv Kumar Sarin2.   

Abstract

OBJECTIVE: Tumor location is a critical factor for determining technical success and local recurrence following percutaneous ablation of hepatocellular carcinomas (HCC). The purpose of this retrospective study was to evaluate the safety and outcome measures of percutaneous microwave ablation (pMWA) for HCCs <4 cm in difficult locations.
METHODS: Retrospective review included 81 patients who underwent pMWA for HCCs <4 cm. Fourty-three patients (30 males and 13 females; mean age, 61 years) with 53 HCCs located near the diaphragm, heart, gallbladder, kidney, gastrointestinal tract, large vessel and exophytic location were included under difficult location group. Thirty-eight patients (29 males and nine females; mean age, 60 years) with 48 HCCs in other locations were included under control group. Baseline demographics were recorded. Technical efficacy, local tumor progression (LTP), and complication rates were evaluated.
RESULTS: Mean follow-up period was 3.4 months (range 1-7). There was no major complication in both the groups; two patients had a mild perihepatic hemorrhage in the difficult location group which was managed conservatively. There was no difference between the groups in the overall technical efficacy rate (84.9% vs 91.7%, p = 0.294), LTP rate (4.4% vs 2.2%. p = 0.57) or complication rate (4.6% vs 0%, p = 0.177).
CONCLUSION: Our data suggest that there is no significant difference in technical efficacy, LTP or complication rates for MWA in both difficult and normal locations. ADVANCES IN KNOWLEDGE: With proper patient selection, pre-procedural planning and appropriate technique, pMWA is feasible, safe, and effective for small HCCs in difficult location with an acceptable range of complications.

Entities:  

Mesh:

Year:  2020        PMID: 32970472      PMCID: PMC7716003          DOI: 10.1259/bjr.20191025

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  24 in total

1.  Efficacy of microwave versus radiofrequency ablation for treatment of small hepatocellular carcinoma: experimental and clinical studies.

Authors:  Guo-Jun Qian; Neng Wang; Qiang Shen; Yue Hong Sheng; Jie-Qiong Zhao; Ming Kuang; Guang-Jian Liu; Meng-Chao Wu
Journal:  Eur Radiol       Date:  2012-04-28       Impact factor: 5.315

2.  EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma.

Authors: 
Journal:  J Hepatol       Date:  2012-04       Impact factor: 25.083

3.  Percutaneous microwave and radiofrequency ablation for hepatocellular carcinoma: a retrospective comparative study.

Authors:  Ming-De Lu; Hui-Xiong Xu; Xiao-Yan Xie; Xiao-Yu Yin; Jun-Wei Chen; Ming Kuang; Zuo-Feng Xu; Guang-Jian Liu; Yan-Lin Zheng
Journal:  J Gastroenterol       Date:  2005-11       Impact factor: 7.527

4.  Safety and Efficacy of Percutaneous Microwave Hepatic Ablation Near the Heart.

Authors:  George A Carberry; Amanda R Smolock; Mircea Cristescu; Shane A Wells; Timothy J Ziemlewicz; Meghan G Lubner; J Louis Hinshaw; Christopher L Brace; Fred T Lee
Journal:  J Vasc Interv Radiol       Date:  2017-02-10       Impact factor: 3.464

5.  Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice Committee.

Authors:  Omid Khalilzadeh; Mark O Baerlocher; Paul B Shyn; Bairbre L Connolly; A Michael Devane; Christopher S Morris; Alan M Cohen; Mehran Midia; Raymond H Thornton; Kathleen Gross; Drew M Caplin; Gunjan Aeron; Sanjay Misra; Nilesh H Patel; T Gregory Walker; Gloria Martinez-Salazar; James E Silberzweig; Boris Nikolic
Journal:  J Vasc Interv Radiol       Date:  2017-07-27       Impact factor: 3.464

6.  Computed tomography-guided percutaneous microwave ablation of hepatocellular carcinoma in challenging locations: safety and efficacy of high-power microwave platforms.

Authors:  Dimitrios K Filippiadis; Stavros Spiliopoulos; Chrysostomos Konstantos; Lazaros Reppas; Alexis Kelekis; Elias Brountzos; Nikolaos Kelekis
Journal:  Int J Hyperthermia       Date:  2017-09-03       Impact factor: 3.914

7.  Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma.

Authors:  S Rajesh; Amar Mukund; Ankur Arora; Deepak Jain; Shiv K Sarin
Journal:  J Vasc Interv Radiol       Date:  2013-06-21       Impact factor: 3.464

Review 8.  Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Josep M Llovet
Journal:  Semin Liver Dis       Date:  2010-02-19       Impact factor: 6.115

9.  Percutaneous tumor ablation: increased coagulation by combining radio-frequency ablation and ethanol instillation in a rat breast tumor model.

Authors:  S N Goldberg; J B Kruskal; B S Oliver; M E Clouse; G S Gazelle
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

10.  Radiofrequency and microwave ablation of subcapsular hepatocellular carcinoma accessed by direct puncture: Safety and efficacy.

Authors:  Giampiero Francica; Maria Franca Meloni; Ilario de Sio; Amanda R Smolock; Christopher L Brace; Maddalena Diana Iadevaia; Roberto Santambrogio; Sandro Sironi; Mariano Scaglione; Fred T Lee
Journal:  Eur J Radiol       Date:  2016-02-01       Impact factor: 3.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.